Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ml355
2. N-(1,3-benzothiazol-2-yl)-4-((2-hydroxy-3-methoxyphenyl)methylamino)benzenesulfonamide
1. Ml355
2. 1532593-30-8
3. Ml355 Free Base
4. Ml-355
5. Vlx-1005
6. Jku4xcc48y
7. Chembl3113165
8. N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide
9. Benzenesulfonamide, N-2-benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)-
10. N-2-benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)benzenesulfonamide
11. N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]-benzenesulfonamide
12. Ncgc00263773-03
13. N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]benzenesulfonamide
14. Unii-jku4xcc48y
15. Gtpl8752
16. Schembl16646023
17. Bcp28954
18. Ex-a1987
19. Bdbm50447175
20. Ml 355
21. S6557
22. Ml 355;ml-355
23. Zinc103266485
24. Cs-3351
25. Ncgc00263773-01
26. Ncgc00263773-18
27. Ac-36858
28. Bs-15552
29. Hy-12341
30. B8014
31. A908037
32. Q27087172
33. N-(2-benzothiazolyl)-4-(2-hydroxy-3-methoxybenzylamino)benzenesulfonamide
34. N-(benzo[d]thiazol-2-yl)-4-(2-hydroxy-3-methoxybenzylamino)benzenesulfonamide
35. Ml-355; Ml-355;n-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide
| Molecular Weight | 441.5 g/mol |
|---|---|
| Molecular Formula | C21H19N3O4S2 |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 441.08169844 g/mol |
| Monoisotopic Mass | 441.08169844 g/mol |
| Topological Polar Surface Area | 137 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 651 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A VLX-1005 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of VLX-1005, including repackagers and relabelers. The FDA regulates VLX-1005 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. VLX-1005 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A VLX-1005 supplier is an individual or a company that provides VLX-1005 active pharmaceutical ingredient (API) or VLX-1005 finished formulations upon request. The VLX-1005 suppliers may include VLX-1005 API manufacturers, exporters, distributors and traders.
VLX-1005 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of VLX-1005 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right VLX-1005 GMP manufacturer or VLX-1005 GMP API supplier for your needs.
A VLX-1005 CoA (Certificate of Analysis) is a formal document that attests to VLX-1005's compliance with VLX-1005 specifications and serves as a tool for batch-level quality control.
VLX-1005 CoA mostly includes findings from lab analyses of a specific batch. For each VLX-1005 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
VLX-1005 may be tested according to a variety of international standards, such as European Pharmacopoeia (VLX-1005 EP), VLX-1005 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (VLX-1005 USP).
LOOKING FOR A SUPPLIER?
